A home-based ePRO tool for symptom management and tracking for cancer patients, clinicians and caregivers
Session type: E-poster/poster
Self-management in cancer is increasingly recognised as critical to improving outcomes and reducing healthcare costs. Better self-management has been linked to lower hospitalisations and lower patient anxiety. Studies show that encouraging patients to log patient-reported outcome (PRO) data prompts more timely and effective patient-clinician communication, and improves clinical decision-making, patient outcomes and care satisfaction.
Yet, self-management remains prohibitively difficult for patients. Digital tools that improve patient activation and the ability to self-manage are particularly important during COVID-19, when interactions with the healthcare team are reduced. This study examines patient engagement with the Vinehealth mobile app; a novel home-based ePRO and self-management tool.
Between January and August 2020, 1121 cancer patients voluntarily signed up to use the ePRO home-based mobile application. Through this tool, longitudinal patient-reported symptom and adverse event data were collected using digital scales based on CTCAE-V5. Longitudinal medication adherence data were collected using the NHS Digital SNOMED CT medication list and quality of life was qualitatively assessed through semi-structured phone interviews. Patients were offered evidence-based educational material to support self-management.
The tool was well used by patients across a wide variety of cancer types (76 different cancer sub-types), the commonest being breast, colorectal, prostate and sarcoma. Average age of the patient cohort was 49±14 years. Cancer patients logged their mood, symptoms and medications 22,200 times over8 months, with medications and symptoms most commonly logged. The majority of symptom logs were to report cancer-related fatigue (CRF) and general well-being. Being able to choose from a comprehensive list of medications, patients reported being on 277 different medication treatments. Evidence-based educational material was accessed 1667 times, covering 32 different topics (the most popular being wellbeing advice, side effect management and dietary suggestions), and patients engaged with 95% of all available content.
This study demonstrates high patient engagement with a home-based tool for ePRO data and self-management and supports the acceptability of such a tool with relevant patient populations. Further evaluation is planned to explore the value of sharing ePRO data logged through the tool with clinicians to support clinical decision-making and remote care.